$1.36
-0.07 (-4.90%)
Open$1.41
Previous Close$1.43
Day High$1.45
Day Low$1.35
52W High$3.08
52W Low$0.87
Volume—
Avg Volume1.32M
Market Cap103.39M
P/E Ratio—
EPS$-1.52
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+107.4% upside
Current
$1.36
$1.36
Target
$2.82
$2.82
$1.78
$2.82 avg
$3.37
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 19.42M | 19.36M | 17.02M |
| Net Income | -2,266,322 | -2,263,432 | -1,770,857 |
| Profit Margin | -11.7% | -11.7% | -10.4% |
| EBITDA | -3,805,934 | -3,485,255 | -2,994,447 |
| Free Cash Flow | -1,809,844 | -1,626,073 | -1,604,802 |
| Rev Growth | +9.6% | -8.7% | +9.0% |
| Debt/Equity | 1.27 | 1.74 | 1.38 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |